The company has asked the U.S. patent office to reconsider patents that could prevent it from selling an update to Keytruda.

Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech ...

While the company is in discussions to acquire SpringWorks, it did not elaborate on these talks in its earnings call.

Merck’s MRK fourth-quarter revenue grew 7% to $15.6 billion (including Keytruda growth of 21% to $7.8 billion), in line with overall 7% growth for the year. Shares fell more than 10% as Merck ...

Merck & Co. (NYSE:MRK) is a prominent American multinational pharmaceutical company many investors know for its brand-name drugs such as Keytruda, and the myriad of commercials the company shows ...